<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0D8E8879-0792-49DD-9598-3984A6BEA513"><gtr:id>0D8E8879-0792-49DD-9598-3984A6BEA513</gtr:id><gtr:firstName>Alessio</gtr:firstName><gtr:surname>Ciulli</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FG023123%2F1"><gtr:id>356968E7-9B59-4466-8470-563879CCAF7C</gtr:id><gtr:title>DISSECTING AND EXPLOITING MOLECULAR RECOGNITION AT PROTEIN-PROTEIN INTERFACES</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>BB/G023123/1</gtr:grantReference><gtr:abstractText>Proteins regulate many of the processes that are crucial for the activity of a living cell. In order to successfully carry out their biological function, proteins often interact in complex with other proteins. The principal subject of the proposed research concerns the development of new approaches to advance our understanding of protein-protein interactions and of how we could disrupt these interactions using the binding of a small molecule. In this project, I focus on studying the binding of small molecules to protein interfaces. I pose the following questions: what features of protein interfaces determine binding and activity (or lack thereof) of a small molecule? Can we modify protein interfaces so that a small molecule can 'stick' to the surface better and better? What can we learn from these new interfaces? How can we use such information to discover new compounds that could function in the cell by binding tightly to these sites? To interrogate protein interfaces, I will first use protein engineering, a technique to generate mutations on a protein by changing amino acids, the building blocks of proteins, from one type to another. I will make mutations in a defined manner, by replacing large amino acids at the protein interface with smaller and smaller ones, hence creating larger and larger cavities. The location and strength of small molecules bound to these engineered pockets will be determined. This will provide useful information to find other protein interfaces that may be functional in living organisms, and that may have the potential to be disrupted using small molecules. Secondly, I will exploit this knowledge further to facilitate identification of small molecules that function by disrupting a protein interface. I will develop new methods to detect small molecules that bind together to adjacent sites of the interface. For this purpose, I will use nuclear magnetic resonance (NMR) spectroscopy, a technique that allows monitoring the hydrogen atoms of small molecules and that can report if these are bound to a protein close to one another. I will also make crystals of the protein in which the interface is accessible to small molecules, and let these molecules react together as they are bound close to each other at the protein surface. Since the structure of a small molecule bound to the protein can be determined directly by shooting X-ray radiations at the protein crystal, a technique called X-ray crystallography, this is a rapid way of identifying any compound that has successfully assembled at the protein interface. The research is important and exciting for the following reasons: 1. Protein interfaces tend to be relatively flat and featureless, as they were not 'evolved' by nature to bind small molecules. The modulation of protein-protein interactions using small molecules is therefore a challenging task, and is at the forefront of molecular recognition. 2. A new scientific horizon is to advance our understanding of biological systems by disrupting pathways and networks in a selective fashion inside the cell. As protein-protein interactions occur widely within the cell, their modulation using small molecules offers an opportunity to interrogate and discover new biology. 3. The disruption of protein-protein complexes offers a novel and general mechanism to develop new medicines. In conclusion, this research has the potential to significantly impact on the way new biology and new drugs will be discovered in the future, with wider benefits to society and exciting opportunities in the fight against disease.</gtr:abstractText><gtr:technicalSummary>The overall objective of this fellowship application is to advance our fundamental understanding of molecular recognition at protein interfaces by small organic compounds. The project will employ a unique combination of molecular biology and biophysical studies of protein-ligand interactions to dissect the nature of non-covalent interactions at protein interfaces, and to exploit such knowledge with the goal of aiding small molecule design. I will study the interaction of small peptides and fragment-like compounds (MW &amp;lt; 300 Da) to the tumour suppressor Von Hippel-Lindau (pVHL), a protein which is part of a complex responsible for the degradation of the Hypoxia-Inducible Factor (HIF-1) inside the cell. I will use protein engineering to make larger and larger cavities at the pVHL:HIF-1 interface with the aim to bind small molecule with increasingly higher affinities. I will study the fundamental changes to the recognition of the small molecules in terms of structure (using X-ray crystallography) and thermodynamics (using low c value isothermal titration calorimetry). This information will provide a platform for future studies in the following two directions: 1) to find structurally similar protein interfaces that may be druggable, using computational tools and structural databases; 2) to facilitate discovery of novel small molecules that bind with high affinity and specificity to a protein interface, using intermolecular Nuclear Overhauser Effect to identify fragments binding at adjacent sites by NMR spectroscopy, and Dynamic Combinatorial X-ray Crystallography to assemble fragments together in the presence of a protein crystal, with the aim of selecting the highest affinity compound. Together these studies will provide significant new insights into the principles that govern the modulation of protein-protein interactions using small molecules, and new tools for studying systems of biological importance and therapeutic potential.</gtr:technicalSummary><gtr:fund><gtr:end>2013-04-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>907791</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Ion mobility mass spectrometry to interrogate the structure and assembly of multisubunit protein complexes</gtr:description><gtr:id>8EA33F21-E6A3-4BEB-BAE3-A4EAD41A5CE4</gtr:id><gtr:impact>Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198.</gtr:impact><gtr:outcomeId>56d95f234ed807.97143030-1</gtr:outcomeId><gtr:partnerContribution>They performed native nanoelectrospray ionization mass spectrometry and traveling wave ion mobility MS experiments on our samples and analyzed data.</gtr:partnerContribution><gtr:piContribution>We expressed and purified component subunits of the SOCS2-CRL E3 ligases assembled into specific complexes and provided the samples to the collaborator (Prof. Frank Sobott research team)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Structure Guided Structure Activity Relationship for VHL Binder Based Protacs</gtr:description><gtr:id>621ACA8D-55E1-46F9-824A-604C7422836B</gtr:id><gtr:impact>1) Establishment of a Protein Degradation DPU within GSK in January 2013
2) Patent: Compounds and Methods for the Inhibition of VCB E3 Ubiquitin Ligase
United States Provisional Patent Application No. 61/585,736 (Filing Date: 12 Jan 2012)
PCT/US2013/021136 (filing date January 11, 2013)
WO 2013/106646 (International publication date July 18, 2013)
3) Patent: Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
United States Provisional Patent Application No. 61/585,769 (Filing Date: 12 Jan 2012)
PCT/US2013/021141 (filing date January 11, 2013)
WO 2013/106643 (International publication date July 18, 2013)</gtr:impact><gtr:outcomeId>5464bd033d58d5.09953326-1</gtr:outcomeId><gtr:partnerContribution>Synthesized several compounds informed by the structural information elucidated by my laboratory using X-ray crystallography. Provided material and intellectual input.</gtr:partnerContribution><gtr:piContribution>this collaboration aims to discover novel small molecule ligands that induce the degradation of any target protein by recruiting the human VHL E3 ubiquitin ligase. My research team solved &amp;gt;20 crystal structures with small molecules synthesized or identified by GSK researchers bound and provided intellectual input and shared materials and expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Cellzome Ltd</gtr:department><gtr:description>Chemoproteomics of native protein complexes</gtr:description><gtr:id>02DA9A6C-730A-431A-82D1-A26D4DE40176</gtr:id><gtr:impact>Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198.

Galdeano, Julianty et al. under revision</gtr:impact><gtr:outcomeId>5464c21002e077.56309962-1</gtr:outcomeId><gtr:partnerContribution>They performed chemoprotemics studies with our compounds, involving pull-down assays from cell lysates and mass spectrometric measurements to assess composition of recruited proteins and binding affinities of compounds</gtr:partnerContribution><gtr:piContribution>We provided Cellzome with compounds to be used in chemoproteomics studies to recruit native E3 Ubiquitin ligase protein complexes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>BioNMR collaborative project BIO-NMR-00169 entitled: Targeting and characterising multi-protein complexes in Fragment-based drug discovery. Small molecules binding to VHL E3 Ubiquitin Ligase and protein binding partners studied by NMR spectroscopy.</gtr:description><gtr:id>546029A2-9F5E-4CFD-8FCC-A92A002FFDC6</gtr:id><gtr:impact>multi-disciplinary collaboration, involving NMR spectroscopy, biophysics, protein purification and characterization and drug discovery.

Dias, D.M., Ciulli, A.* NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes. Prog Biophys Mol Biol, 2014, 116(2-3), 101-112</gtr:impact><gtr:outcomeId>5464d104304829.30408051-1</gtr:outcomeId><gtr:partnerContribution>provide access to NMR instrumentation and facilities and provided intellectual input</gtr:partnerContribution><gtr:piContribution>purified protein samples for NMR spectroscopic studies and provided intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Massachusetts Institute of Technology (MIT)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Application of fragment-based screening towards development of selective inhibitors of protein N-glycosylation pathways in pathogenic gram-negative bacteria</gtr:description><gtr:id>8C1A9BCE-8991-41EC-A458-706178E70228</gtr:id><gtr:impact>Postdoctoral report, James P. Morrison (MIT)
PhD thesis, Michael Morrison (MIT)</gtr:impact><gtr:outcomeId>b9619266b961927a-1</gtr:outcomeId><gtr:partnerContribution>Led small molecule inhibitor design efforts that initiate as the results of our biophysical fragment screening results</gtr:partnerContribution><gtr:piContribution>This collaboration expands the range of protein binding-site targets for druggability studies. Our preliminary results have identified fragments targeting sugar binding sites, traditionally considered poorly tractable with small molecules, an adjacent site where cofactor CoA binds, as well as an inter-subunit interface of the homo-trimeric bacterial enzyme. These provide exciting opportunities to further develop some of the concepts and hypothesis that are central to my Fellowship proposal. My work on fragment screening and computational design complements nicely with the expertise of the Imperiali lab and efforts on synthetic chemistry, enzyme inhibition and structural studies ongoing in her lab</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>Development of selective chemical tools to interrogate protein-protein interactions involved in the epigenetic regulation of gene transcription</gtr:description><gtr:id>A3713658-BD89-4685-B485-3A13FD75E882</gtr:id><gtr:impact>1) PhD thesis, Fleur M. Ferguson (University of Cambridge)
2) 10. Tallant, C., Valentini, E., Fedorov, O., Overvoorde, L., Ferguson, F.M., Filippakopoulos, P., Svergun, D., Knapp, S., Ciulli, A.* Molecular basis of histone tail recognition by human TIP5 PHD finger and Bromodomain of the chromatin remodelling complex NoRC. Structure, 2015, 23(1), 80-92.
3) Ferguson, F.M., Fedorov, O., Chaikuad, A., Philpott, M., Muniz, J., Felletar, I., von Delft, F., Heightman, T.D., Knapp, S., Abell, C., Ciulli, A.* Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design Against the BAZ2B Bromodomain. J. Med. Chem., 2013, 56(24), 10183-10187
4) Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletar, I., Ciulli, A., Knapp, S., Heightman, T.D. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol. Biosyst., 2011, 7, 2899-2908</gtr:impact><gtr:outcomeId>b95ff712b95ff730-1</gtr:outcomeId><gtr:partnerContribution>Provided reagents and material, access to instrumentation, and intellectual input
Solved a number of crystal structures
Hosted team members for short visits</gtr:partnerContribution><gtr:piContribution>This collaboration has been concentrated initially on the human bromodomains, protein domains that recognize acetylated lysine residues on histone proteins. This project is directly relevant to the Fellowship since it is an example, like pVHL-HIF, of a protein-protein interaction where molecular recognition appears to be dictated by a key post-translational modification of one of the two partner proteins</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>BioNMR collaborative project 261863 proposal no. BIO-NMR-00211 entitled: Structural modelling and dynamics of the Bromodomain Adjacent to Zinc finger domain containing protein 2B bromodomain</gtr:description><gtr:id>CF0B1B95-1308-4C13-96C9-5DAC775A66F6</gtr:id><gtr:impact>13. Ferguson, F.M., Dias, D.M., Rodrigues, J.P.G.L.M., Wienk, H., Boelens, R., Bonvin, A.M.J.J., Abell, C., Ciulli, A.* Binding hotspots of BAZ2B bromodomain: histone interaction revealed by solution NMR driven docking. Biochemistry, 2014, 53(42), 6706-6716.</gtr:impact><gtr:outcomeId>5464d1fa0bf0b5.68057454-1</gtr:outcomeId><gtr:partnerContribution>Provided access to NMR facility and provided intellectual input and expertise</gtr:partnerContribution><gtr:piContribution>Purified proteins to be used in NMR spectroscopic studies and binding assyas, and provided intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of drug-like small molecule ligands targeting human pVHL protein: towards the next-generation of PROTAC molecules for targeted protein degradation</gtr:description><gtr:id>11DBA02C-E4DA-47D1-9A54-5289974DB188</gtr:id><gtr:impact>1) Buckley, D.L., Gustafson, J.L., Van Molle, I., Roth, A.G., Tae, H.S., Gareiss, P.C., Jorgensen, W.L., Ciulli, A., Crews, C.M. Small Molecules Inhibitors of the Interaction Between the E3 Ligase VHL and HIF1a. Angew. Chem. Int. Ed., 2012, 51, 11463-11467
2) Van Molle, I., Thomann, A., Buckley, D.L., So, E.C., Lang, S., Crews, C.M., Ciulli, A.* Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:Hypoxia Inducible Factor 1a protein-protein interface. Chem. Biol., 2012, 19, 1300-1312
3) Buckley, D.L., Van Molle, I., Gareiss, P.C., Tae, H.S., Michel, J., Noblin, D.J., Jorgensen, W.L., Ciulli, A.*, Crews, C.M. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1a interaction. 
J. Am. Chem. Soc., 2012, 134, 4465-4468
4) PhD thesis, Dennis Buckley (Yale University)
5) Patent: Compounds and Methods for the Inhibition of VCB E3 Ubiquitin Ligase
United States Provisional Patent Application No. 61/585,736 (Filing Date: 12 Jan 2012)
PCT/US2013/021136 (filing date January 11, 2013)
WO 2013/106646 (International publication date July 18, 2013)
6) Patent: Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
United States Provisional Patent Application No. 61/585,769 (Filing Date: 12 Jan 2012)
PCT/US2013/021141 (filing date January 11, 2013)
WO 2013/106643 (International publication date July 18, 2013)
7) Spin-out company Arvinas, Yale University (founder: Prof. Craig Crews)</gtr:impact><gtr:outcomeId>b95ff47eb95ff492-1</gtr:outcomeId><gtr:partnerContribution>Synthesized and tested over 100 compounds that were informed by our crystallographic structural and biophysical binding studies and fragment-based approaches</gtr:partnerContribution><gtr:piContribution>this collaboration aims to discover novel small molecule ligands that target human pVHL, thus it is highly synergistic with the Fellowship proposed research on druggability of pVHL. As the lab focuses efforts on synthetic chemistry and biochemical and cellular assays in vitro and in vivo, it is also highly complementary to my efforts in structural and biophysical studies of protein-ligand interactions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media press release: Bump-and-hole approach brings protein breakthrough</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F830DB73-03DB-4537-8A08-8D4FE01CEFDF</gtr:id><gtr:impact>Media press release covering my laboratory recent article published in Science

After this press release, I have received a notable number of emails from other colleagues and friends to congratulate us with our achievement but also to tell me that they read the press release and this stimulated their interest in learning more about the topic of epigenetics and small molecule chemical biology and drug discovery. Many individuals have already contacted me to make requests for reagents, and many companies interested in this area have also approached me to express their willingness and interest to collaborate with us.

see:
http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx
http://www.lifesci.dundee.ac.uk/news/2014/oct/22/ciulli-labs-bump-and-hole-approach-leads-protein-breakthrough</gtr:impact><gtr:outcomeId>5464cd37c993d6.86468700</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alessio delivers the course Drug Discovery to the Dept. of Pharmaceutical Chemistry at the University of Messina, under the realm of the new MIUR-funded programme Messaggeri della Conoscenza</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>467C03D0-A680-4A8B-BEC8-4DF4E08375FB</gtr:id><gtr:impact>Taught a course in Drug Discovery which sparked questions, discussions and further interaction. Hosted 4 selected students in my laboratory the following year, and disseminated all activities, also in the form of a video publicly accessible online

Students, teachers and public in Italy more aware of the important of exchange programmes between Italy and UK</gtr:impact><gtr:outcomeId>5464cf74901bc3.49889026</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=GxrQwJO9HB8</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>578328</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Responsive Mode grant: A systems approach for the fragment-based development of selective chemical probes of bromodomain function</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/J001201/1</gtr:fundingRef><gtr:id>14D1B99F-E3F4-4110-A72E-E851F2DE41C0</gtr:id><gtr:outcomeId>5ee51df45ee51dfe</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107977</gtr:amountPounds><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Foundation of Science and Technology (FCT)</gtr:department><gtr:description>Portuguese FCT Studentship</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Government of the Portugese Republic</gtr:fundingOrg><gtr:fundingRef>SFRH/BD/81735/2011</gtr:fundingRef><gtr:id>EF18F148-7CF8-4933-A1A5-2A0CAE24BD21</gtr:id><gtr:outcomeId>r-2977138713.91223606870104</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie Intra-European Fellowships for Career Development (IEF)</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>EU FP7-PEOPLE-2012-IEF 328030 orthoPROTACS</gtr:fundingRef><gtr:id>06756519-10A6-4C21-87EF-A1F5890C9878</gtr:id><gtr:outcomeId>546235cecb94e1.66043653</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Doctoral Training Account PhD Studentship</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>awarded, however student did not move from Cambridge to Dundee so funding reallocated to a different PI</gtr:fundingRef><gtr:id>0755BB0E-DB96-4155-940A-AE31EB71C673</gtr:id><gtr:outcomeId>546234674d2166.72944457</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>169110</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Intra-European Fellowships for Career Development (IEF)</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>FP7-PEOPLE-2010-IEF-275683 pVHL-CRL</gtr:fundingRef><gtr:id>762C90AD-817F-47F6-86B0-63D8598365C5</gtr:id><gtr:outcomeId>5ec642b25ec642c6</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Doctoral Training Account PhD Studentship</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>fees-only, awarded but withdrawn because other full-cost funding was found</gtr:fundingRef><gtr:id>E4DA69F6-9F0A-4385-93F2-702401CAC5AA</gtr:id><gtr:outcomeId>5462315fbae723.36899374</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>MIUR Messaggeri della Conoscenza - Drug Discovery</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Italian Ministry of Education, Universities and Research</gtr:fundingOrg><gtr:fundingRef>ID 497 - Drug Discovery</gtr:fundingRef><gtr:id>851B4B15-05D8-418A-93E0-7ABFA7D6FB69</gtr:id><gtr:outcomeId>546236c8f069a8.05766206</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GSK grant: Structure Guided Structure Activity Relationship for VHL Binder Based Protacs</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:fundingRef>RG Number:    67080;  UFS Project:   MAAG/937</gtr:fundingRef><gtr:id>2FB4D5C6-238B-4CCC-A500-7EA9E67650B3</gtr:id><gtr:outcomeId>546233fb358f60.77038583</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Doctoral Training Account PhD Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>A7C66180-8E6F-4DBC-89DC-512EA05B81BF</gtr:id><gtr:outcomeId>5ee616825ee61696</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC Starting Grant: DrugE3CRL</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>ERC Starting Grant 311460 DrugE3CRLs</gtr:fundingRef><gtr:id>AB4D3D4F-30E2-4DAD-86AF-B3335A0F14A2</gtr:id><gtr:outcomeId>5462355b7f7df2.07191448</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The breakthrough discoveries made by our laboratory and collaborators of potent VHL ligands have led not only to several publications, but also two patents (US 2014356322 and WO 2013106646), and to the establishment of Yale spin-off Arvinas in the US and a Discovery Platform Unit (DPU) within GlaxoSmithKline Stevenage, UK. Such activity represents tangible output of Dr. Ciulli's research in terms of impact, innovation and commercial exploitation. Arvinas and the GSK DPU are pharmaceutical companies both focused on developing small molecule strategies aimed at degrading disease- causing cellular proteins, with a focus in oncology amongst other therapeutic areas.</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>2D7CB8A5-BD44-4111-9465-1449C3CCBA05</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56df07aaa56e01.34299200</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to novel compounds which find utility as modulators especially inhibitors of the VCB E3 Ubiquitin ligase and as bioactive agents for use as therapeutics.
United States Provisional Patent Application No. 61/585,736 (Filing Date: 12 Jan 2012)
PCT/US2013/021136 (filing date January 11, 2013)</gtr:description><gtr:grantRef>BB/G023123/1</gtr:grantRef><gtr:id>C125E74A-9A55-4C7B-8D47-F8E5C752BC7E</gtr:id><gtr:impact>1) Spin-out company Arvinas, Yale University (founder: Prof. Craig Crews)
2) Establishment of a Protein Degradation Discovery Platform Unit (DPU) within GSK</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-7806436445.3837627668e9cc</gtr:outcomeId><gtr:patentId>WO 2013/106646</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Compounds and Methods for the Inhibition of VCB E3 Ubiquitin Ligase</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to bifunctional compounds which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention.
United States Provisional Patent Application No. 61/585,769 (Filing Date: 12 Jan 2012)
PCT/US2013/021141 (filing date January 11, 2013)
WO 2013/106643 (International publication date July 18, 2013)</gtr:description><gtr:grantRef>BB/G023123/1</gtr:grantRef><gtr:id>879BA716-5EA2-4DEC-AEC3-C85CEB29AC27</gtr:id><gtr:impact>1) Spin-out company Arvinas, Yale University (founder: Prof. Craig Crews)
2) Establishment of a Protein Degradation Discovery Platform Unit (DPU) within GSK</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-3803511963.974237669105a</gtr:outcomeId><gtr:patentId>WO 2013/106643</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>1) VHL-HIF inhibitors. In collaboration with Craig Crews (Yale University), we have discovered first-in-class small molecules that bind the E3 CRL component von-Hippel Lindau protein (VHL) and disrupt its interaction with substrate Hypoxia Inducible Factor alpha subunit (HIFa) (Van Molle et al., Chem. Biol., 2012; Buckley et al., J. Am. Chem. Soc. 2012; Angew. Chem. Int. Ed. 2012). More recently, my laboratory conducted extensive rational design, guided by liganded crystal structures and biophysical binding characterization, to improve the binding affinity and physicochemical properties of the compounds (Galdeano et al., J. Med. Chem 2014). These exciting discoveries and the resulting filed patents have led to the establishment of spin-off company Arvinas in the U.S. and of a Discovery Platform Unit (DPU) in Protein Degradation within GSK.

2) Ligandability of CRLs. Using the VHL-HIFa inhibitors as a starting point, we have carried out fundamental analyses of what type of ligands can more effectively probe PPIs and what approaches can best find these molecules (Van Molle et al., Chem. Biol., 2012; Dias et al., ACS Med. Chem Lett., 2014). This research is increasing our understanding of the druggability of PPIs, which helps to intervene effectively and reduce risks associated with tackling such challenging targets.

3) CRL complexes. Using a hybrid approach combining biophysical and structural techniques in innovative ways, and in collaboration with experts in ion-mobility native mass spectrometry (Dr. Djana Matak-Vinkovic, Cambridge and Prof Frank Sobott, Antwerp) and chemoproteomics (Dr Paola Grandi, GSK-Cellzome), we have dissected in increasing level of detail the molecular structure, assembly and interactions of components of complexes and their PTMs within the CRL5-ASB9 (Thomas et al., Biochemistry, 2013) and CRL5-SOCS2 (Bulatov et al., J. Biol. Chem., 2015; Gadd et al., Plos One, 2015).</gtr:description><gtr:exploitationPathways>by exploiting their potential as chemical tools and therapeutics</gtr:exploitationPathways><gtr:id>DA37AD4B-DDBE-47B2-B6DC-F78B1607D147</gtr:id><gtr:outcomeId>56df0a190f73a0.80765206</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4AF9C761-29DE-4710-9199-B14A4731A885</gtr:id><gtr:title>Targeting Bacillosamine Biosynthesis in Bacterial Pathogens: Development of Inhibitors to a Bacterial Amino-Sugar Acetyltransferase from Campylobacter jejuni.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7d7773644c52e61dc250611b59e5409"><gtr:id>d7d7773644c52e61dc250611b59e5409</gtr:id><gtr:otherNames>De Schutter JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>58c9f86080b1a7.88050615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF29EA00-907B-45FD-BFA4-0161F0F9C097</gtr:id><gtr:title>NMR of Biomolecules - Towards Mechanistic Systems Biology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df3b72a3a23e9ddd32f2e074bedfe7d1"><gtr:id>df3b72a3a23e9ddd32f2e074bedfe7d1</gtr:id><gtr:otherNames>Sledz P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>9783527328505</gtr:isbn><gtr:outcomeId>doi_53cfbffbf2c40074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86E438EF-9084-49BC-AAE2-4F6ADA723ACD</gtr:id><gtr:title>Biophysical characterization of laforin-carbohydrate interaction.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41655ec6cfb913faa9ce0aaa91d7cf0"><gtr:id>b41655ec6cfb913faa9ce0aaa91d7cf0</gtr:id><gtr:otherNames>Dias DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56d6d38bc90914.33353137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A318BE92-C4E7-47A3-BCC3-B25AF6FED0B3</gtr:id><gtr:title>Biophysical screening for the discovery of small-molecule ligands.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e36715ebcc37ef7255f27df8cf9cf78"><gtr:id>9e36715ebcc37ef7255f27df8cf9cf78</gtr:id><gtr:otherNames>Ciulli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>54648c4615e513.39374053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6728A8F3-AD11-44CB-8619-3C3A9F76CEB7</gtr:id><gtr:title>Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1a.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26b76abffeef118d23db034840639ee"><gtr:id>f26b76abffeef118d23db034840639ee</gtr:id><gtr:otherNames>Buckley DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>54648c45e3dc91.07079161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F36983F-8D23-42D8-8BF4-F09081AE6591</gtr:id><gtr:title>Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95f82d1838b6e50a181a9bccf589c569"><gtr:id>95f82d1838b6e50a181a9bccf589c569</gtr:id><gtr:otherNames>Bulatov E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5675ddc64e47c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE502A08-334A-435F-84DF-33120239F2DD</gtr:id><gtr:title>Targeting the von Hippel-Lindau (pVHL) E3 Ubiquitin Ligase multisubunit protein complex using small molecules to disrupt its interaction with Hypoxia Inducible Factor 1 alpha (Hif-1a)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_9521111232140c0c06</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F826D6EC-16B4-40E4-BF36-2E9FEF2A149A</gtr:id><gtr:title>Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1a interaction.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26b76abffeef118d23db034840639ee"><gtr:id>f26b76abffeef118d23db034840639ee</gtr:id><gtr:otherNames>Buckley DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>pm_5435af55af5e53abf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D24FAC26-829D-4AE6-8C24-8D8163B3CFD3</gtr:id><gtr:title>New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6f5b6d9d45da6947e03cf0095933fb8"><gtr:id>e6f5b6d9d45da6947e03cf0095933fb8</gtr:id><gtr:otherNames>Baud MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>56d6d2b78ca825.35551028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBDAD089-9FB1-40F6-8AB6-52528D88E973</gtr:id><gtr:title>Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1&amp;Icirc;&amp;plusmn; protein-protein interface.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/875e67b507a5d0560ce86b40f0f411c9"><gtr:id>875e67b507a5d0560ce86b40f0f411c9</gtr:id><gtr:otherNames>Van Molle I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>54648c45be0b56.94173971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE1FFE37-ACB2-457F-BED3-E7DBE2324256</gtr:id><gtr:title>Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95f82d1838b6e50a181a9bccf589c569"><gtr:id>95f82d1838b6e50a181a9bccf589c569</gtr:id><gtr:otherNames>Bulatov E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>doi_55f94b94bdc8a0f4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C68D3C1-E683-48DE-AF19-E129448B22C7</gtr:id><gtr:title>Studies towards the discovery of small molecules that disrupt the VHL:HIF-1_ interaction.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>m_2634650016140c0b34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>268371DE-4122-4395-9253-552CBBDECBF0</gtr:id><gtr:title>Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cad2b40a955b692fba0474cf6776934"><gtr:id>8cad2b40a955b692fba0474cf6776934</gtr:id><gtr:otherNames>Gadd MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e784d2be7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59891D4A-9A9C-443E-984E-D01E1BEB6377</gtr:id><gtr:title>Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9f34089081372afc64353e7d4f940b2"><gtr:id>b9f34089081372afc64353e7d4f940b2</gtr:id><gtr:otherNames>Philpott M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>pm_5435af55af5d95290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32F8420F-85B0-44D1-969E-9677061549B9</gtr:id><gtr:title>Interrogating macromolecular complexes using fragment-based small-molecule approaches: the multiprotein von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>m_5987380192140c09a4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ECF2978-4E8E-4C08-9354-12BF6C4866DF</gtr:id><gtr:title>Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd022f2a0dd7d6b6f0330e226d06c264"><gtr:id>bd022f2a0dd7d6b6f0330e226d06c264</gtr:id><gtr:otherNames>Baud MGJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>54648b4951f337.39631105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A8E4C40-6F17-428E-91C4-F9512F914BA8</gtr:id><gtr:title>Interactions, assembly and fragment screening of the multisubunit SOCS2-EloBC-Cul5-Rbx2 E3 ubiquitin ligase</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41b3de4d227e96cec8fd1f843260e613"><gtr:id>41b3de4d227e96cec8fd1f843260e613</gtr:id><gtr:otherNames>Bulatov Emil</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5464cb23798435.25668803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DDC30CF-FD0C-4FA6-9836-1427F8114104</gtr:id><gtr:title>A novel approach to engineer selectivity of bromodomain chemical probes</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5464b24fd445e8.24992320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51C69E86-7383-4440-89A3-3EC84568D422</gtr:id><gtr:title>Molecular basis of histone tail recognition by human TIP5 PHD finger and bromodomain of the chromatin remodeling complex NoRC.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5fc71630c08928905cfee490fcc0fb5"><gtr:id>a5fc71630c08928905cfee490fcc0fb5</gtr:id><gtr:otherNames>Tallant C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>5464b83519d407.16717096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A869E39-EB37-4B75-B4F2-A480EC1CD55B</gtr:id><gtr:title>Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98971b7b99422190e6dd2ca3fdd2950e"><gtr:id>98971b7b99422190e6dd2ca3fdd2950e</gtr:id><gtr:otherNames>Ferguson FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>54648c45735b58.01398011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86CC1911-124C-4FEB-97E6-BDDB1E61ECB0</gtr:id><gtr:title>Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2595b4a7cfd27964cd44b6e1b564763"><gtr:id>e2595b4a7cfd27964cd44b6e1b564763</gtr:id><gtr:otherNames>Galdeano C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>54648b49af02a5.91817814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4797743A-58FB-4603-93E6-E01B1D0C681D</gtr:id><gtr:title>A novel approach to engineer selectivity of bromodomain chemical probes</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5464b16810a558.96163563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87A0FBC5-1099-41F2-B70A-F1561B86994C</gtr:id><gtr:title>Binding hotspots of BAZ2B bromodomain: Histone interaction revealed by solution NMR driven docking.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98971b7b99422190e6dd2ca3fdd2950e"><gtr:id>98971b7b99422190e6dd2ca3fdd2950e</gtr:id><gtr:otherNames>Ferguson FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>54648b498d7369.57733838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FB98370-D117-411E-9816-F4CD5EBEF895</gtr:id><gtr:title>NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes.</gtr:title><gtr:parentPublicationTitle>Progress in biophysics and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41655ec6cfb913faa9ce0aaa91d7cf0"><gtr:id>b41655ec6cfb913faa9ce0aaa91d7cf0</gtr:id><gtr:otherNames>Dias DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0079-6107</gtr:issn><gtr:outcomeId>54648c45246049.65563279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81C234F9-0EF6-414D-A5FC-DA61530C2D73</gtr:id><gtr:title>Targeting the von Hippel-Lindau multisubunit Cullin RING E3 ubiquitin ligase using small molecules to disrupt its interaction with Hypoxia Inducible Factor 1 a subunit</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5464b0c71ced11.52879639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>940DDF98-D45C-45A3-8326-5A5A22CDA3E2</gtr:id><gtr:title>Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein Interactions?</gtr:title><gtr:parentPublicationTitle>ACS medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41655ec6cfb913faa9ce0aaa91d7cf0"><gtr:id>b41655ec6cfb913faa9ce0aaa91d7cf0</gtr:id><gtr:otherNames>Dias DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1948-5875</gtr:issn><gtr:outcomeId>54648c454d9da9.18242294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFC627EC-ED08-41C9-8602-EF5CDFD654C1</gtr:id><gtr:title>Multimeric complexes among ankyrin-repeat and SOCS-box protein 9 (ASB9), ElonginBC, and Cullin 5: insights into the structure and assembly of ECS-type Cullin-RING E3 ubiquitin ligases.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c4d6f6138fd6bd9d704db192be26001"><gtr:id>0c4d6f6138fd6bd9d704db192be26001</gtr:id><gtr:otherNames>Thomas JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>54648c459998a3.88077493</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/G023123/1</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>356968E7-9B59-4466-8470-563879CCAF7C</gtr:id><gtr:grantRef>BB/G023123/1</gtr:grantRef><gtr:amount>907791.74</gtr:amount><gtr:start>2010-01-01</gtr:start><gtr:end>2013-04-07</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>0E81F16A-93CA-4CE4-9ED6-1FB701974D46</gtr:id><gtr:grantRef>BB/G023123/2</gtr:grantRef><gtr:amount>307126.04</gtr:amount><gtr:start>2013-04-08</gtr:start><gtr:end>2015-07-07</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>